KBC Group NV Increases Stake in Biogen Inc. $BIIB

KBC Group NV grew its stake in Biogen Inc. (NASDAQ:BIIB) by 50.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 53,398 shares of the biotechnology company’s stock after buying an additional 17,939 shares during the quarter. KBC Group NV’s holdings in Biogen were worth $9,397,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Invesco Ltd. boosted its stake in shares of Biogen by 4.2% in the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after buying an additional 98,001 shares during the period. AQR Capital Management LLC boosted its stake in shares of Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after buying an additional 418,776 shares during the period. Legal & General Group Plc boosted its stake in shares of Biogen by 10.1% in the 3rd quarter. Legal & General Group Plc now owns 1,593,399 shares of the biotechnology company’s stock valued at $223,203,000 after buying an additional 146,583 shares during the period. Pacer Advisors Inc. boosted its stake in shares of Biogen by 9.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,451,249 shares of the biotechnology company’s stock valued at $203,291,000 after buying an additional 131,258 shares during the period. Finally, Man Group plc boosted its stake in shares of Biogen by 15.7% in the 3rd quarter. Man Group plc now owns 918,025 shares of the biotechnology company’s stock valued at $128,597,000 after buying an additional 124,743 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on BIIB shares. Royal Bank Of Canada decreased their price objective on Biogen from $233.00 to $213.00 and set an “outperform” rating for the company in a research note on Tuesday, April 7th. Oppenheimer raised their target price on Biogen from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. HC Wainwright raised their target price on Biogen from $228.00 to $237.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Wells Fargo & Company raised their target price on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. Finally, Guggenheim raised their target price on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Thirteen equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $208.23.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by company insiders.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Zacks highlighted Biogen in a roundup noting broker attention and solid earnings momentum, which can support investor interest and buying flows. Zacks.com featured highlights include Biogen, TE Connectivity and ZTO Express (Cayman)
• Neutral Sentiment: Analysts on aggregate maintain a “Hold” consensus on BIIB, suggesting limited near-term analyst-driven upside despite recent beats; this keeps expectations tempered. Biogen Inc. (NASDAQ:BIIB) Receives Average Rating of “Hold” from Analysts
• Neutral Sentiment: Multiple outlets note mixed analyst opinions and interest in Biogen alongside other healthcare names — useful for tracking sentiment shifts but not an immediate catalyst. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Nkarta (NKTX)
• Neutral Sentiment: Investor-focused pieces (Zacks/Value Investor write-ups, TipRanks roundup) are prompting renewed attention to BIIB as a value/growth trade; these can influence retail flows but carry no new company-specific fundamentals. Should Value Investors Buy Biogen (BIIB) Stock? Spotify, Sandisk, Natera, Biogen, Tesla Trending With Analysts
• Negative Sentiment: A new scientific report questions how much benefit Alzheimer’s drugs such as Leqembi (Biogen/Eisai) and Kisunla deliver, raising potential regulatory, reimbursement and demand risks for Biogen’s Alzheimer’s franchise — this is the most direct negative near-term headline and could pressure shares if it affects uptake or payor support. These Alzheimer’s drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

Biogen Trading Up 0.8%

BIIB opened at $177.35 on Friday. The firm has a market cap of $26.03 billion, a price-to-earnings ratio of 20.13, a price-to-earnings-growth ratio of 2.36 and a beta of 0.16. Biogen Inc. has a 52 week low of $115.25 and a 52 week high of $202.41. The business’s 50 day moving average is $185.82 and its two-hundred day moving average is $174.10. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts predict that Biogen Inc. will post 15.83 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.